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Abstract
There is much interest in defining the signals that initiate ab-
normal proliferation ofcells in a varietyofstates characterized
by the presence of mononuclear phagocytes. Since IL-I is a
major secretory product ofactivated human monocytes we ex-
amined whether this cytokine can stimulate the growth of
human vascular smooth muscle cells (SMC). Neither recombi-
nant IL-1 (rIL-1) a (' 5.0 ng/ml) nor , (c 100 ng/ml) stimu-
lated SMC growth during 2-d incubations under usual condi-
tions. IL-1 did stimulate SMC to produce prostanoids such as
PGE, or PGE2 thatcaninhibit SMCproliferation. When pros-
taglandin synthesis was inhibited by indomethacin or aspirin
both rIL-1 a and 6 (2 1 ng/ml) markedly increased SMC
growth. In longer-term experiments (7-28 d) rIL-1 stimulated
the growth of SMC even in the absence of cyclooxygenase
inhibitors. The addition ofexogenous PGE, or PGE2 (but not
PGFIa, PGFu, PGI2) to indomethacin-treated SMC blocked
their mitogenic response to rIL-l. Antibody to IL-1 (but not to
platelet-derived growth factor [PDGFI) abolished the mito-
genic response ofSMC to rIL-1. Exposure ofSMCto rIL-1 or
PDGF caused rapid (maximal at 1 h) and transient (baseline
by 3 h) expression ofthe c-fos proto-oncogene, determined by
Northern analysis. We conclude that IL-1 is a potent mitogen
for human SMC. Endogenous prostanoid production simulta-
neously induced by IL-1 appears to antagonize this growth-
promoting effect in the short term (2 d) but not during more
prolonged exposures. IL-1 produced by activated monocytes at
sites of tissue inflammation or injury may thus mediate both
positive and negative effects on SMC proliferation that are
temporally distinct.
Introduction
The control ofcellular proliferation is a fundamental biologi-
cal problem that has considerable practical importance in re-
lation to certain human diseases. Forexample, the pathogene-
sis ofatherosclerosis and hypertension involve abnormal pro-
liferation of smooth muscle cells (SMC)' within the arterial
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1. Abbreviations used in this paper: ASA, acetylsalicylic acid; FGF,
fibroblast growth factor; HSVSMC, human saphenous vein SMC; IT,
wall (1, 2). Definition offactorsthat may regulateproliferation
ofthese cells has received considerable attention over the last
dozen years. The platelet was an early contender as the source
ofmitogens that stimulate the growth ofSMC during athero-
genesis (3). However, in the cholesterol-fed animal, SMC pro-
liferation commences while the endothelial monolayer that
lines the vessel's lumen remains intact, and before the adher-
ence and degranulation ofplatelets at the site ofthe lesion (4).
These observations indicate that initiation ofatherogenesis in
vivo does not require products released from platelets.
Morphologic studies ofthe sequence ofevents in the wall
ofarteries ofanimals fed cholesterol have stimulated interest
in the role ofphagocytic leukocytes in plaque formation. Soon
after initiation ofcholesterol feeding, blood monocytes adhere
to thearterialintimaanddiapedese throughitsyetintact endo-
thelial monolayer (5-9). Focal accumulations of lipid-laden
macrophages in the intima characterize the fatty streak, the
lesion that precedes the complicated fibrous plaque character-
istic ofadvanced atherosclerosis, and that contains accumula-
tions ofSMC in addition to phagocytes (10, 11). These obser-
vations have focused attention on monocyte products that
may stimulate the proliferation ofmesenchymal cells such as
SMC(12, 13).
One of the mitogens secreted by activated mononuclear
phagocytes resembles platelet-derived growth factor (PDGF).
Upon stimulation, human monocytes can transcribe the genes
that encode both chains of PDGF and secrete material that
cross reacts immunologically with PDGF purified from
human platelets and that shares its mitogenic activity (14-16).
Monocytes also produce the mitogen transforming growth
factor a (Madtes, D. K., E. W. Raines, K. S. Sakariassen, R. K.
Assoian, M. B. Sporn, G. I. Bell, and R. Ross, personal com-
munication) as well as material that resembles fibroblast
growth factor (FGF) (17). Upon activation, these cells secrete
large amounts of the multipotent mediator IL-1 (18, 19).
Among the many functions ascribed to the IL-1 family of
molecules isthe ability to stimulate theproliferation ofhuman
fibroblasts (20), although its mitogenic effects on these cells
can be weak or inconsistent (21). IL-1 does have a degree of
sequence homology with the acidic FGF family (22). There-
fore, it was ofinterest to determine ifIL-l also promoted the
growth ofhuman vascular SMC and might thus participate in
the abnormal proliferation ofthis cell type that occurs early in
atherogenesis.
In previous studies we failed to demonstrate a mitogenic
effect ofIL-1 on vascularSMC from a variety ofspecies gener-
ally studied over a 2-d period (23). IL-1 characteristically stim-
ulatestheproduction ofprostaglandins from targettissues, and
serum-free chemically defined medium supplemented with insulin (1
MM) and transferrin (5 qg/ml); PDGF, platelet-derived growth factor;
PDS, plasma-derived serum; rIL-l, recombinant human IL-1; SMC,
smooth muscle cells.
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(24-26). Since prostaglandins ofthe E sernes can inhibit mito-
gen-induced proliferation of cultured vascular SMC (27), in
our previous experiments endogenous prostanoids induced by
IL-1 might have masked a direct mitogenic effect ofthis hor-
mone. Our earlier study ofthe proliferative action ofIL-1 on
mesenchymal cells used material purified from activated
human monocytes that contained an incompletely defined
mixture ofthetwo known species ofhuman IL-1, a andf3. The
present study used homogenous preparations ofIL-1 a and ,B
producedbyrecombinant DNA technology from genescloned
from human monocytes (28-30) to reexamine the possible
mitogenic effect of IL-l on vascular SMC during longer pe-
riods of exposure, and under conditions that prevented the
synthesis ofendogenously produced prostanoids.
Methods
Cell preparation, culture, and characterization. SMC were prepared
from human saphenous veins by explant outgrowth techniques (31).
The saphenous vein specimens were trimmnings obtained at coronary
artery bypass surgery. This use of usually discarded tissue was ap-
proved by the Human Investigation Review Committee ofNew En-
gland Medical Center. The cell cultures were maintained in DME
buffered with Hepes (25 mM) (M. A. Bioproducts, Walkersville, MD).
Very low concentrations of bacterial endotoxin (<100 pg/ml) can
stimulate endogenous IL-l production by these cells (32). Endotoxin
contamination oftissue culture reagents could thus confound the re-
sults of study of the effects of exogenous recombinant IL-I (rIL-l)
preparations. Therefore, constituents of tissue culture media were
screened forendotoxin contamination using thequantitative chromo-
genic limulus amoebocyte lysate assay (QCL 1000; M. A. Biopro-
ducts). Onlymaterialswithendotoxin levels < 40 pgsperml were used
in theseexperiments. Inaddition, theendotoxin antagonistpolymyxin
B (10 ,ug/ml) was included in all experimental incubations.
These cells cultured from saphenous vein explants (passage 2 to 5)
exhibited typical morphologic characteristics ofvascular smooth mus-
cle in vitroincludingapattern ofgrowth in hills andvalleys (31). Even
after three passages in culture the majority of these cells exhibited
specific immunofluorescence when stained with a monoclonal anti-
body that selectively recognizes muscle forms ofactin (HHF 35). This
reagent does not react with endothelial cells or fibroblasts (33). These
immunofluorescence studies were kindly performed by Dr. T. Tsu-
kada, E. W. Raines, Or. A. M. Gown, and Dr. R. Ross ofthe Depart-
ment of Pathology, University ofWashington, Seattle, WA. Human
aortic SMC were isolated enzymatically from the inner third of the
tunica media ofhuman arteries obtained from transplant donorswith
the cooperation ofthe New England Organ Bank (34).
Reagents. IL-la prepared by recombinant DNA technology in
Escherichia coli was provided by Dr. Peter T. Lomedico ofHoffman-
La Roche Inc., Nutley, NJ. This preparation consists ofthe carboxy-
terminal 154 amino acids ofthe 271 residue human IL-la precursor
(30). IL-1I3(residues 112 to 269) producedbyrecombinant DNAtech-
nology in E. coli was supplied by Dr. Charles A. Dinarello, Tufts
University (35). Dr. Dinarello also supplied an ammonium sulfate
(40% saturated) precipitate from rabbit anti-serum raised against
human rIL-la. We prepared an IgG fraction from this material by
protein A affinity chromatography.
Highly purified PDGF from human platelets was provided by
Elaine W. Raines and Russell Ross (36). These investigators also gen-
erously supplied us with goatanti-human PDGFIgG. Theprobe used
to detect c-fos mRNA was a 1-kb Eco RI fragment ofv-fos proviral
DNA (37). The cDNA probe used to detect,3-tubulin transcript was a
highly conserved I kb segment of a rat #l-tubulin gene from pSP-6
RBT.3 (38) that encodes a protein constitutively expressed in many
tissues. We prepared this construct from a cDNA clone provided by
Dr. Stephen R. Farmer ofBoston University Medical School, Boston,
MA (39). The cyclooxygenase inhibitors indomethacin and acetylsali-
cylic acid (ASA) (aspirin) were purchased from Sigma Chemical Co.,
St. Louis, MO.
Growth assays. For growth assays, cells were subcultured into 24-
wellplatesat 3 X 104cm-2 orin 96-wellplatesat0.9-2 X 105cm-2. The
cultures in 24-well plates were maintained in DME with FCS (10%)
until they were postconfluent (11-14 d postsubculture). One day be-
fore initiation ofgrowth studies, these cultures wereplaced in medium
composed of equal parts of DME and Ham's F-12 medium (M. A.
Bioproducts) lacking serum butsupplementedwith insulin (1 MM)and
transferrin (5 Ag/ml) (Collaborative Research, Bedford, MA), a me-
diumdenoted IT. Thisincubationin serum-freemediumwasdesigned
to deprive the cells ofserum-associated mitogens and produce growth
arrest in an attempt to synchronize cell proliferation in response to
mitogens added during growth assays (40). The cultures in 96-well
plates were used for experiments 2 d after subculture without preincu-
bation in serum-free medium unless otherwise specified.
Incorporation oftritiated TdR (6 Ci/mmol, ICN Radiochemicals,
Irvine, CA) was measured in short-term assay by addition ofthe la-
beled TdR (0.05 MCi/ml for 24-well plates; 0.25 MCi/ml for 96-well
plates) during the second 24 h of a 48-h incubation. In pilot experi-
ments on human saphenous vein SMC (HSVSMC), this schedule of
labeling maximized stimulation of TdR incorporation exposed to a
known mitogenic stimulus, FCS. At the end ofthe incubation unin-
corporated precursor was removed by treatment with perchloric acid
(0.2 M) or by washing with distilled water cell residues collected on
filter paper by an automated cell harvester. Radioactivity was mea-
sured by liquid scintillation spectroscopy, and efficiency ofcounting
was determined by use ofan external standard.
DNA measurements were made on perchloric acid-treated cell
layers by a fluorimetric procedure based on binding ofbisbenzamide
(Calbiochem-Behring Diagnostics, La Jolla, CA) (40, 41). As an addi-
tional index ofculture mass, cells were stained with the protein-bind-
ing dye amido black lOB (napthol blue black or buffalo black NBR;
SigmaChemical Co.) accordingtothe methodofVilcek etal. (42). For
this assay the layers were fixed in formalin (10%) in sodium acetate
buffer (0.1 M) for 15 min, and treatedwith asolution ofthedye(0.5%)
in acetic acid (9%) with sodium acetate (0.1 M) for 10-30 min. After
three washes in distilled water to remove unbound dye, the cell layers
could be photographed. Subsequently, the bound dye was extracted in
sodium hydroxide (50 mM) and the absorbance ofthis solution at 630
nm measured.
Measurement ofprostaglandins. The major prostanoids produced
by human vascularsmooth muscle arePGE2, PGF2a, andprostacyclin
(25, 43-45). PGE2, PGF2a, and the stable metabolite ofprostacyclin,
6-keto PGFI,, were measured in the supernatants of SMC cultures
using radioimmunoassay. The prostanoids were extracted from the
acidified culture media with ethyl acetate. After drying by vacuum
evaporation, the residue was dissolved in phosphate buffer that con-
tained bovine -y-globulin. Assays for theprostanoids used commercial
radioimmunoassay kitsaccording to themanufacturer'srecommenda-
tions (Seragen Inc., Boston, MA). The antibody used for the PGE2
assay crossreacts completely with PGE,, 1.3% with PGF2a and < 1%
with 6-keto PGFI.. The antibody used to detect PGF2a crossreacts
completely with PGFi,a, 1.1% with PGE,, 1.1% with 6-keto PGFI,,
and 0.3% with PGE2. The antibody used to detect 6-keto PGFi,a
crossreacts 7.8% with PGF1,, 6.8% with 6-keto PGE,, 2.2% with
PGF2a, 0.7% with PGE1, and 0.6% with PGE2.
RNA extraction and blot hybridizations. RNA was extracted from
SMC by treatment with guanidinium isothiocyanate and isolated by
centrifugation throughcesium chloride(46). ForNorthernblotting, 10
yg oftotal cellular RNA was applied to each lane. DNA probes were
labeled by nick translation with dCT32P and dGT32P (New England
Nuclear, Boston, MA) to specific activities > 5 X 108 cpm/Mg DNA.
Electrophoresis and transfer to nylon membranes (Hybond-N; Amer-
sham Corp., Arlington Heights, IL), fixation, hybridization, and auto-
radiography used standardtechniques (32, 38).
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IL-I stimulatesthegrowth ofculturedhuman vascularSMCin
thepresenceofa cyclooxygenase inhibitor. Incubation ofSMC
cultured from adult HSVSMC in DME with FCS (5%) that
contained various concentrations of rIL- 1 a or (3 did not in-
crease TdR incorporation, which was measured during the
final 24 h of the 48-h experiment (Fig. 1, A and B, open
squares). These results agree with our previous studies that
used IL-1 purified from activated human blood monocytes
(23). IL-l stimulates prostanoid production by SMC, and cer-
tain prostaglandins can inhibit the proliferative response of
these cells to PDGF (27). Therefore, we performed this experi-
ment in parallel on cells incubated with the cyclooxygenase
inhibitorindomethacin at aconcentration (1 ,ug/ml) that com-
pletely blocks the synthesis of PGE2 by these cells (Table I)
(26). Under this condition, both species of rIL-1 increased
TdR incorporation even at the lowest concentration tested
(Fig. 1, A and B, closed squares).
Thymidine incorporation alone is a potentially misleading
index ofcell proliferation and may not reflect the actual rate of
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Figure 1. Concentration dependence ofrIL-1-induced stimulation of
TdR incorporation by human vascular SMC with orwithout indo-
methacin. Cultures ofHSVSMC in 24-multiwell plates were incu-
bated for 48 h with the indicated concentrations ofrIL-Ia (A) or ,
(B). In the absence ofindomethacin there was little or no change in
TdR uptake measured between 24 and 48 h during this 2-d incuba-
tion (open squares). In the presence ofindomethacin (1 ug/ml) rIL-
increased TdR uptake by HSVSMC (closedsquares). The data points
represent the mean ofsix observations and the error bars the SD.
Table I. rIL-1 Increases Prostaglandin Release
from Human Vascular SMC
Stimulus Inhibitor PGE2 6-Keto-PGF,. PGF2.
ng/ml/48 h ng/ml/48 h ng/mI/48 h
None None 0.6±0.1 0.5±0.2 0.4±0.1
ASA 0.4±0.1 0.2±0.1 0.3±0.1
INDO 0.4±0.1 0.3±0.1 0.3±0.1
rIL-Ia (1 ng/ml) None 41.9±0.4 16.1±2.3 3.5±0.3
ASA 3.0±0.3 1.2±0.2 0.4±0.1
INDO 0.4±0.1 0.1±0.1 0.2±0.1
rIL-1# (10 ng/ml) None 40.6±9.0 21.3±0.6 4.3±0.5
ASA 4.1±0.1 1.5±0.4 0.5±0.1
INDO 0.4±0.1 0.2±0.1 0.2±0.1
Data are the means±SD ofthree observations; SD < 0.1 are rounded
up to 0.1. ASA (0.1 mM). INDO, Indomethacin (1 jg/ml).
DNA synthesis under some circumstances. Therefore, we also
measured the accumulation of DNA by HSVSMC cultured
with or without rIL-l a or $ for 0-14 d in the presence of
indomethacin (1 gg/ml). In this experiment, there was little or
no net growth ofthe cultures incubated in medium that con-
tained FCS alone at asuboptimal concentration (5%) as deter-
mined by the DNA content measured in extracts (Fig. 2, trian-
gles). Cultures incubated with the addition of either rIL-1a
(Fig. 2, open squares) or rIL-l3 (Fig. 2, closed squares) accu-
mulated DNA in a time-dependent manner. These phenom-
ena were not limited to SMC ofvenous origin, asboth rIL-1 a
and # in the presence ofindomethacin increased TdR uptake
by cultures of human aortic SMC prepared by collagenase
dissociation (Table II).
IL-I-induced SMC growth does not depend on serum-
associated mitogens. The foregoing experiments showed that
IL-1 stimulated growth of cultured human vascular SMC.
However, all ofthese experiments were performed in the pres-
6
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Figure 2. rIL-1 a or , increases DNA accumulation in cultures of
human vascular SMC. HSVSMC were incubated in 24-multiwell
plates with DME containing FCS (5%) alone (triangles) or with the
addition ofrIL-Ia (1 ng/ml) (open squares), or rIL-1# (10 ng/ml)
(closedsquares), all in the presence ofindomethacin (1 Mg/ml). DNA
content was determined at the outset ofthe experimental incubation
and after 4, 8, or 14 d. Data are mean±SD ofsix observations.
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by Human Aortic SMC
[3H]Thymidine incorporation
- Indomethacin + Indomethacin
dpm/weIl/24 h dpm/welI/24 h
Control (FCS 5%) 2,752±415 3,150+435
rIL-la (1 ng/ml) 1,325±334 6,966+2,227
rIL-1I# (10 ng/ml) 1,537±98 7,064+911
ence of FCS (5%), which contains mitogens such as PDGF.
Therefore, these experiments did not determine whether IL-1
potentiated PDGF or other serum-associated mitogens or
could stimulate proliferation of HSVSMC in the absence of
other growth factors. To address this issue we performed addi-
tional experiments that exposed HSVSMC cultures in parallel
to rIL-la (1 ng/ml) with or without indomethacin in a variety
ofmedium supplements. As before, rIL-1 stimulated TdR in-
corporation by HSVSMC incubated with FCS (5 or 2%) only
in the presence ofindomethacin (Fig. 3, crosshatched bars). In
the absence ofIL-1, the lowerconcentration ofFCS (2%) stim-
ulated less TdR incorporation than did FCS (5%) (Fig. 3,
compare darkly and lightly crosshatched bars). Other condi-
tions in this experiment used plasma-derived serum (PDS)
prepared from horse blood and obtained commercially (Hy-
Clone Laboratories, Logan, UT). This material isprepared in a
manner that limits the concentrations of coagulation-asso-
ciated mitogens including PDGF (47). In pilot experiments
this lot ofPDS caused little or no growth ofhuman or bovine
vascular SMC, but supported the proliferation ofbovine aortic
SMC after the addition of highly purified PDGF (data not
shown). Baseline measurements showed that PDS alone
caused less TdR incorporation than did equivalent concentra-
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Figure 3. IL-1 stimulates TdR incorporation by human vascular
SMC in the presence or absence ofserum-associated mitogens. Cul-
tures ofHSVSMC in 96-multiwell plates were incubated in DME
containing FCS (2 and 5%), horse PDS (2 and 5%), and in IT. The
cell cultures were maintained in the various media without further
addition, in the presence ofindomethacin (1 ,ug/ml), with rIL-1a (1
ng/ml) alone, or in a combination ofIL-1 and indomethacin for 48
h. Uptake of[3H]TdR was measured during the second 24 h ofthis
2-d incubation. Data are mean±SD ofeight observations.
tions of FCS. rIL-la added to medium containing PDS (5 or
2%) caused an approximately threefold increase in TdR incor-
poration in the presence of indomethacin (Fig. 3, stippled
bars).
This experiment also evaluated the ability ofrIL-1 to stim-
ulate TdR incorporation in HSVSMC cultures incubated in
serum-free chemically defined medium supplemented with
insulin (1 j,M) and transferrin (5 jig/ml) (IT). rIL-1 stimulated
TdR incorporation in the absence of any serum-associated
mitogen (Fig. 3, solid bars). This finding shows that like
PDGF, IL-1 stimulates cell proliferation in a simple medium
that contains insulin or insulin-like factors (47, 48).
rIL-is stimulate prostaglandin production by cultured
human vascular SMC. IL-1 characteristically stimulates pros-
tanoid production by target tissues. Several laboratories have
found that monocyte-derived IL-1 increases prostaglandin
production by vascular SMC (24-26). We tested the effects of
rIL-Is on the release ofprostaglandins by adult human vascu-
lar SMC (Table I). HSVSMC were incubated in 96-well plates
in DME containing FCS (5%) for 2 d. Under basal conditions,
these cells elaborated negligible amounts of PGE2, 6-keto
PGFia (the stable metabolite of prostacyclin), or PGF2,a, the
major products of the cyclooxygenase pathway in vascular
smooth muscle (24, 25). rIL-1 a or : augmented the release of
these prostanoids manyfold (Table I), at concentrations that
stimulated TdR incorporation in an identical culture ofthese
cells incubated in the presence of indomethacin (data not
shown). The cyclooxygenase inhibitors, indomethacin (1
gg/ml) and aspirin (ASA, 0.1 mM), both inhibited the in-
creases in prostaglandin production that were induced by IL-1
(Table I).
Prostaglandins induced by IL-i inhibit the short-term mi-
togenic effect ofthis hormone on SMC. We hypothesized that
rIL-ls failed to stimulate growth of HSVSMC because of si-
multaneous induction of the synthesis of growth-inhibitory
prostanoids. To explore this possibility further we studied the
relationship between the ability ofrIL-1 to stimulate TdR in-
corporation by HSVSMC when prostanoid production was
blocked to varying degrees. Indomethacin at 0.1 ,ug/ml com-
pletely prevented synthesis of PGE2 by IL-1-stimulated
HSVSMC (Fig. 4, top). This concentration of indomethacin
also maximally augmented TdR incorporation in the same
experiment. A concentration of indomethacin (0.01 ,ug/ml)
that blocked PGE2 production incompletely permitted an in-
termediate rise in TdR incorporation in response to rIL-1 (Fig.
4, top). Another inhibitor ofcyclooxygenase, ASA, produced a
similar pattern. Concentrations ofASA that incompletely in-
hibited PGE2 production also permitted only partial mitogenic
response to rIL-1 (Fig. 4, bottom). The reciprocal relationship
between TdR incorporation and prostanoid production in
IL-1-stimulated HSVSMC, demonstrated by the effect of
these two different cyclooxygenase inhibitors at varying con-
centrations, supports the concept thatendogenous prostanoids
limit the mitogenic response ofHSVSMC to IL-1 in such ex-
periments.
As an additional test for this hypothesis, we added exoge-
nous prostanoids to HSVSMC incubated with IL-13 (10
ng/ml) in the presence ofa concentration ofindomethacin (1
,ug/ml) that abolished endogenous prostanoid production.
Both exogenous PGE, and PGE2 (Sigma Chemical Co.) pro-
duced concentration-dependent inhibition of IL- -induced
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Figure 4. Inverse relationship between prostanoid production and
TdR incorporation in human SMC cultures incubated with IL-I in
the presence ofvarying concentrations ofcyclooxygenase inhibitors.
HSVSMC cultures in 96-multiwell plates were incubated for 48 h in
DME containing FCS (5%) alone or in the presence ofrIL-Ia (1.0
ng/ml) with the indicated concentrations ofeither indomethacin or
ASA. In one set ofidentical cultures, the medium was collected after
48 h and analyzed for PGE2 by radioimmunoassay (n, n = 3,
mean±SD). The values marked by asterisks may be underestimated
since these PGE2 measurements were at the upper limit ofthe assay.
In parallel cultures, TdR incorporation was measured during the last
24 h ofthe 48-h incubation (o, n = 8, mean±SD).
TdR incorporation (Fig. 5). The range of concentration of
these prostanoids tested (1-20 ng/ml) corresponded to those
actually produced by cultured HSVSMC stimulated by IL-1
(Table I, Fig. 4). An independent experiment with rIL-1a
yielded almost identical results (data not shown). In yet an-
other similar experiment, PGF1,, and PGF2, (both studied at
1-20 ng/ml) did not inhibit IL-l-induced increases in TdR
incorporation by indomethacin-treated HSVSMC (data not
shown). This finding indicated that this inhibitory effect was
most likely due to prostaglandins ofthe E series.
IL-I produces morphologic changes and stimulates SMC
growth even in the absence ofcyclooxygenase inhibitors in
longer-term experiments. The above experiments that exam-
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0no Ind
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human vascular SMC. Cultures ofHSVSMC in 96-well plates were
incubated with DME containing FCS (5%) and the indicated condi-
tions for 48 h. Thymidine incorporation was measured during the
last 24 h ofthis 2-d incubation. Prostaglandins were added at the in-
dicated concentrations to cells incubated in medium that contained
both IL-1,B(IO ng/ml) and indomethacin. The asterisks indicate a
statistically significant difference (P < 0.01; Student's t test, n = 8)
compared with rIL-1,B in the presence ofindomethacin (the condi-
tion represented by the taller ofthe two open bars).
ined the effect ofcyclooxygenase inhibitors on SMC growth
were limited to 48-h incubations. We also determined the ef-
fect of rIL-1 on cell morphology and growth in longer-term
experiments with or without indomethacin. In preliminary
experiments, we were surprised to find that after I wk ofexpo-
sure to rIL-I a or fl, cultures ofHSVSMC showed significant
alterations in the pattern and extent of growth even in the
absence of indomethacin (data not shown). Therefore, we
studied the effect ofrIL- a (I and 10 ng/ml) on the morphol-
ogy and growth ofHSVSMC incubated in FCS (5%) without
cyclooxygenase inhibitors over a 4-wk-period. Over the first
several days phase-contrast microscopy revealed fittle or no
difference in cellular morphology under these various condi-
tions(data notshown). After4 or 5 dofexposure torIL-ng , the
cells assumed a morebipolar, spindle-shaped appearance (Fig.
6, A-te. At thistime cells incubated with eitherconcentration
of rIL-Ia showed numerous mitotic figures compared with
cultures incubated in FCS (5%) alone (compare Fig. 6 A to 6 B
or 6 C). Phase-coantdifrenc py 01;tinued to reveal evi-
dence ofincreased cell proliferation in the cultures exposed to
rIL-I a as seen by luxuriant multilayer and whorl formation
visible after I wk and continuing for up to 4 wk ofcontinued
exposure (Fig. 6, D-F). Montesano et al. (49) observed similar
elongation and whorl formation in human fetal endothelial
cell cultures exposed to monocyte-derived IL-1. We have also
found that rIL- 1s produce such morphologic changes in adult
human endothelial cell cultures. However, we have so far
failed to demonstrate a mitogenic effoect of IL-1 on human
endothelial cells, even when cultured in the presence ofindo-
methacin (data not shown).
After morethan aweek or so inculture, microscopywas no
longer necessary to observe the abundance ofcellular material
in the IL- d -treated cultures. Inspection oftheunmagnifiedcell
laderthroue h the bottom ofthe culture dish ordurinumedium
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Figure 6. Incubation with rIL-I alters the morphology and growth
pattern ofcultured human vascular SMC. Replicate cultures of
HSVSMC in 12-multiwell plates were incubated in DME with FCS
(5%) alone (A and D) or in the presence ofrIL-Ia at I ng/ml (B and
E) or 10 ng/ml (Cand F). After 5 d (A-C) the IL-I-treated SMC
appeared elongated and bipolar by phase-contrast microscopy. There
changes showed this accumulation macroscopically. At the
end ofthis 4-wk experiment amido black staining confirmed
these observations (Fig. 7, B and C). Spectrophotometric
quantitation ofthe amount ofdye bound by these cell layers
showed a fivefold increase in binding ofthe dye by the IL-I-
treated cell layers (Fig. 7, graph). Amido black probably stains
the cell layer by binding to both intra- and extracellular pro-
teins. This procedure may actually underestimate the amount
ofprotein in the overgrown IL-1-treated wellsbecause the dye
may not have equal access to all cells in the multilayers char-
acteristically formed by SMC in dense cultures. Note that in
both the 2-d (Fig. 1 A) and 28-d (Figs. 6 and 7) experiments 1
ng/ml ofrIL-1a produced nearly as great an effect as a five- to
tenfold higher concentration on all variables studied.
Comparison ofthe mitogenic effects ofIL-I andPDGFon
human vascular SMC in culture. PDGF is the prototypical
smooth muscle mitogen and accounts for much of the
growth-promoting activity found in serum. PDGF has been
highly purified from human platelets, and it was ofinterest to
compare the mitogenic effects of PDGF and IL-1 on
were frequent mitotic figures (white arrows). After 28 d ofincubation
(D-F) the cells maintained in DME with FCS alone retained their
polygonal morphology while the cultures maintained in rIL-Ia (E
and F) show marked accentuation ofthe morphologic changes that
were already observed after 5 d. It was difficult to focus on a single
plane in these latter conditions as there were many layers ofcells.
HSVSMC. PDGF produced near maximal increases in TdR
incorporation at 5 ng/ml (Fig. 8). The addition ofindometha-
cin resulted in only a small increment in TdR incorporation
under these conditions. IL-1a produced a near maximal effect
at 10 ng/ml in the presence ofindomethacin (Fig. 8). In the
absence ofindomethacin, IL-I did notstimulate TdRincorpo-
ration. The failure of indomethacin to increase significantly
the mitogenic effect of PDGF may be because this mitogen
does not induce PGE, or PGE2 release by HSVSMC. Two
independent experiments showed no PGE2 production by
these cellsduring a 48-h incubation with PDGF (0.1-5 ng/ml)
(data not shown).
Studies with selectiveantibodies suggest that themitogenic
effects ofIL-I and PDGF on human vascular SMC are inde-
pendent. Under some circumstances SMC themselves can ex-
press PDGF genes and secrete PDGF like growth-promoting
activity (50-53). It was possible that IL-1 stimulated SMC
proliferation indirectly by inducing endogenous PDGF pro-
duction. We tested whether release ofimmunoreactive PDGF
contributed to the IL-1-induced growth of HSVSMC in ex-
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Figure 8. Comparison ofthe effects ofPDGF and IL-I on TdR in-
corporation by HSVSMC. Cultures ofHSVSMC in 96-multiwell
plates were preincubated in IT for 48 h to arrest cell growth and to
deplete any available serum-associated PDGF. The medium was
then replaced with fresh IT that contained the indicated concentra-
tions ofrIL-la or PDGF highly purified from human platelets. Thy-
midine incorporation was measured during the second 24 h of a 48-h
incubation in the presence or absence ofindomethacin (1 ,ug/ml).
Data are mean ofeight observations.
Figure 7. Prolonged incubation with
rIL-I markedly alters the growth of
human vascular SMC. The same
cell layers presented in Fig. 6 were
stained with amido black and pho-
tographed after the 28-d incubation.
Condition A contained FCS alone,
condition B contained rIL- a (1
ng/ml), and condition C contained
rIL-la (10 ng/ml). Note the macro-
scopic changes in conditions B and
C that corresponded to the phase
microscopic observations presented
in Fig. 6, Eand F. The bar graph
beneath the photograph shows the
amido black binding determined in
extracts ofthese same cell layers.
Data are mean±SD ofthree obser-
vations.
ng/ml) and PDGF (1.5 ng/ml), in the presence ofindometha-
cin (1 ,ug/ml), stimulated TdR incorporation by HSVSMC. In
combination, PDGF and IL-1 produced additive effects (Fig.
9). Addition of monospecific anti-human PDGF IgG com-
pletely inhibited the stimulatory effect ofPDGFon TdRincor-
poration, but did not block the effect ofIL-I either alone or in
the presence ofadded PDGF. In contrast, addition ofanti-IL-
a IgG completely blocked the mitogenic effect ofthe inter-
leukin, but did not affect the stimulatory effect ofPDGF (Fig.
9). The results of these antibody inhibition experiments sup-
port an effect of IL-1 on smooth muscle growth that is inde-
pendent ofmediation by release ofimmunoreactive PDGF.
IL-I rapidly andtransiently induces expression ofthec-fos
proto-oncogene in vascular SMC. Addition ofPDGF or fresh
serum to fibroblasts or SMC rapidly induces mRNA that en-
codes the c-fos proto-oncogene. The product ofthis gene is a
protein associated with the cell nucleus that may be involved
in signaling the early events in commitment to cell division
(54-57). IfIL- 1 were a mitogen for SMC, it should induce this
proto-oncogene. Northern blotting experiments did not reveal
c-fostranscript in RNA isolated from unstimulated HSVSMC.
15 min after addition ofIL-1, c-fos mRNA was detected, and
maximal levels were observed one-halfhour after addition of
the cytokine (Fig. 10). By 3 h, c-fos mRNA was again unde-
tected. Note that PDGF modulated levels ofc-fos mRNA with
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Figure 9. Effect ofselective antibodies on PDGF- and IL-1-induced
stimulation ofTdR incorporation by HSVSMC. Cultures of
HSVSMC in 96-multiwell plates were growth arrested by a 2 d prein-
cubation in IT before the addition ofexperimental media, which was
also compounded in this serum-free medium, incubated for 48 h,
and TdR incorporation was measured during the second 24 h ofthis
incubation. The experimental media, which included indomethacin
(1 Ag/ml), contained rIL-Ia (1 ng/ml) or PDGF (1.5 ng/ml), or a
combination ofboth hormones. The left-hand series ofbars shows
data obtained without antibody. In the incubation depicted in the
middle series ofbars, monospecific goat anti-human PDGF (100
,ug/ml) was included throughout the experimental incubation. In the
incubation depicted in the right-hand series ofbars, rabbit anti-
human IL-la (5 ltg/ml) was present during the experimental incuba-
tion. Data are mean±SD ofeight observations.
an identical time course (Fig. 10). The rapid kinetics of c-fos
induction by IL-1, identical to that produced by PDGF, fur-
ther supports a direct role for IL-1 as a signal for SMC division.
In addition, the lack ofbaseline c-fos expression and the rapid
rise and fall ofthis mRNA indicate that HSVSMC incubated
in IT are indeed growth arrested and respond synchronously to
added mitogens.
Discussion
Proliferation of mesenchymal cells such as fibroblasts and
smooth muscle contributes to fibrogenesis in wound healing as
well as in certain important pathological processes. In the lung
such mesenchymal cell multiplication occurs in interstitial fi-
brosis and granulomatous diseases (21). An analogous situa-
tion may occur in some types of hepatic fibrosis (58). Certain
glomerulopathies also involve proliferative lesions (59). In the
context ofthe blood vessel, multiplication ofvascular SMC is a
key component in formation of the complicated atheroscle-
rotic plaque (1-3). This process may also play a role in the
structural changes in blood vessels that may help sustain or
contribute to progression ofboth systemic and pulmonary hy-
pertension (2).
The presence of phagocytic leukocytes characterizes the
early stages ofthe lesions in several ofthese pathological situa-
tions. Activated mononuclear cells are a likely source ofmedi-
ators that signal cellular proliferation and the synthesis ofmac-
romolecules that contribute to fibrogenesis. PDGF-like mito-
gens account for part of the growth-promoting activity for
mesenchymal cells produced by human macrophages (14-16).
Another candidate is IL-1, a major secretory product of acti-
vated human monocytes. These cells express two distinct genes
that encode protein products that have virtually indistinguish-
able biological activities, although they differ substantially in
their physicochemical properties (60). IL-I has an isoelectric
point near neutrality and is the major form secreted by human
monocytes upon activation; its message may account for
several percent of the mRNA in these cells (28). The other
less abundant species, IL-1 a, has an isoelectric point of - 5
(29, 30).
IL-1I has a degree of sequence similarity with the acidic
FGF/endothelial cell growth factor family (22, 61), and IL- 1
exhibits mitogenic effects on human fibroblasts under certain
circumstances (20, 21). We previously explored the possibility
that IL- 1 can also stimulate the growth of vascular SMC. In
these experiments we failed to demonstrate a mitogenic effect
of IL-1 derived from human monocytes on bovine, rabbit, or
human vascular SMC during 2-d incubations (23). We elected
to reexamine this issue in the current study for several reasons.
It is now apparent that IL-1 is a potent inducer of prostanoid
synthesis in SMC, and that prostanoids of the PGE series can
inhibit the response of vascular SMC to such well-character-
ized mitogens as PDGF(27, 62). The cloning ofIL-1 genes and
the production of rIL-1 species permits more defined experi-
ments than were previously possible. In addition, there have
been considerable improvements in the preparation and char-
acterization ofpreparations ofcultured adult human vascular
smooth muscle available for such studies.
Inhibitory effects of prostaglandins on cell proliferation
were first described in the early 1970s and have been noted in
several contexts (21, 63, 64). We therefore tested whether
blockade of prostanoid synthesis during IL-1 stimulation
would unmask a direct mitogenic effect. The results of short-
term (2 d) experiments were quite striking. In the absence of
cyclooxygenase inhibitors, rIL-1 a or fi consistently failed to
increase proliferation of human vascular SMC, in agreement
with our previous study that used monocyte-derived IL- 1.
However, indomethacin or aspirin, which produced concen-
tration-dependent inhibition ofprostanoid synthesis by IL-1-
stimulated HSVSMC, increased TdR incorporation by these
cells. The concentration dependence of these two reciprocal
effects was identical (Fig. 4, A and B). Addition ofexogenous
PGE1 or PGE2 to IL-1-stimulated HSVSMC, treated with in-
domethacin to block endogenous prostanoid synthesis, inhib-
ited the mitogenic effect of rIL-1 (Fig. 5). Although the anti-
body we used to measure PGE recognized PGEI as well as
PGE2, since both of these compounds inhibit IL- 1-induced
SMC proliferation, this distinction is not critical to the inter-
pretation ofour findings. Thus, our data are consistent with a
direct stimulatory effect of IL-1 on human vascular SMC
growth that is counterbalanced in the short term by an "auto-
crine" inhibitory loop that involves prostaglandins.
Exposure ofHSVSMC to rIL-1 for longer periods(1-4 wk)
caused growth of HSVSMC even in the absence of cyclooxy-
genase inhibitors. The present data do not distinguish between
several possible mechanisms for this "escape" phenomenon.
The prolonged exposure of HSVSMC to rIL-1 could result in
reduced production or responsiveness to prostaglandin. How-
ever, preliminary measurements showed that HSVSMC
treated with IL-1 from 2 to 8 d continued to release PGE2 (data
not shown). The apparent disparity between the acute experi-
ments that involve primarily TdR uptake measurements and
thelonger-termexperiments mightalso reflect aselective effect
ofprostaglandins on TdR uptake orthe specific activity ofthe
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Figure 10. IL-I and
F PDGF rapidly and tran-
siently increase steady
state levels ofc-fos
mRNA in adult human
vascular SMC. Cultures
ofHSVSMC in Petri
plates (15 cm diam) were
washed with Hanks' bal-
anced salt solution, and
growth arrested by main-
tenance for 24 h in IT.
Cultures were then incu-
bated for the indicated
times in IT with indo-
methacin (1 gg/ml) that
contained rIL-l1 (10
ng/ml) or PDGF purified
from human platelets (1
ng/ml). At the end of
each experimental incu-
bation, the medium was
removed and the cell
layer was immediately
dissolved in cold guani-
dinium isothiocyanate so-
lution. RNA was isolated
3 6 h by centrifugation through
cesium chloride. North-
em analysis, transfer, fix-
ation, and hybridization
were performed as pre-
viously described (32,
38). The top shows an au-
toradiogram resulting
from hybridization ofthe
* membrane with v-fos pro-
viral DNA nick translated
to a specific activity of
1.5 x 109 cpm/gg DNA.
The autoradiogram
shown was exposed for 5
d. The bottom shows the
result ofa rehybridization
ofthe same northern blot
with the probe for the constitutively expressed form offi-tubulin, nick translated to a specific activity of9 x 108 cpm/gg DNA. This expo-
sure was for 1 d. The size markers (arrowheads) are the positions ofmigration ofthe 18- and 28-S ribosomal RNA subunits.
TdR precursor pool for DNA synthesis. However, rIL-1
caused small but significant net increases in DNA content in
indomethacin-treated cells over a 2-d period (data notshown).
Also, Nilsson and Olsson (27) showed that PGE, or PGE2
reduced the fraction of nuclei labeled with tritiated TdR in
PDGF-treated rat SMC, an effect unlikely to be due to altered
TdR transport or pool specific activity. Bitterman et al. (21)
also documented that PGE2 reduced labeling indices offibro-
nectin-stimulated fibroblasts.
Factors that regulate cell growth appear to act by a variety
of mechanisms. Certain "growth factors" such as PDGF or
FGF render cells competent to enter S phase. Other factors
(e.g., insulin-like growth factor-I or somatomedin) do not
themselves signal entry of the cells into S phase, but permit
cells prepared fordivision by other signals to progressthrough
the cell cycle (65, 48). High concentrations ofinsulin such as
those used in the defined serum-free medium denoted IT (Fig.
7) are not themselves mitogenic for SMC, but may act like
somatomedin (40). Thus, these results indicate that rIL-1 pre-
pares SMC for entry into the cell cycle in a manneranalogous
to PDGF. The ability of IL-1 to increase c-fos mRNA levels
rapidly and transiently in SMC provides further evidence that
this cytokine may triggerearly events in the commitment pro-
cess for cell division. IL-l and PDGF increased c-fos mRNA
with similar kinetics (Fig. 10). Ourexperiments also showthat
the potency of IL-1 both in promoting growth of HSVSMC
and in modulating c-fos message level is ofthe same order of
magnitude as PDGF (Figs. 8-10).
The results of these studies highlight the potential com-
plexity ofgrowth control in the blood vessel wall. In addition
to positive stimuli such as PDGF, IL-1, and other mitogens,
the regulation of SMC growth probably includes inhibitory
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Since IL-1 induces prostaglandin synthesis by mesenchymal
cells this hormone can stimulate both positive and negative
limbs of growth control. In intact animals, this dual effect
would have the obvious advantage of limiting uncontrolled
cell proliferations in response to these mitogens. Such simulta-
neous induction of stimulatory and inhibitory pathways is
common in the fine regulation ofmany other important bio-
logical systems in vivo, including the neurotransmission,
blood coagulation, and the immune response.
In the case ofIL-1, the existence ofa negative control loop
isparticularly significant in view ofourrecent finding thatthis
family ofhormones stimulates expression ofits own genes by
vascular smooth muscle and endothelial cells (26, 67). Lovett
and colleagues (68, 69) found that renal mesangial cells divide
in response to monocyte-derived IL-1; this cell type can also
express an IL-I gene (70) and elaborate IL-1-like activity that
stimulates its own growth. Production ofIL-I by target tissues
such as smooth muscle and mesangium in vivo could set the
stage for an autostimulatory inflammatory response that
would amplify and extend to the detriment ofthe host. Since
the local inflammatory response seldom propagates uncon-
trolled under normal circumstances in vivo, it is likely that
such inhibitorycontrol loops as we describe here do operate in
the intact organism to modulate this response and limit posi-
tive feedback situations.
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